These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29364929)

  • 1. Real-life effectiveness and safety of salbutamol Steri-Neb™ vs. Ventolin Nebules® for exacerbations in patients with COPD: Historical cohort study.
    Price DB; Gefen E; Gopalan G; McDonald R; Thomas V; Ming SWY; Davis E
    PLoS One; 2018; 13(1):e0191404. PubMed ID: 29364929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in biomarkers of cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease.
    Shafuddin E; Chang CL; Cooray M; Tuffery CM; Hopping SJ; Sullivan GD; Jacobson GA; Hancox RJ
    Respir Med; 2018 Dec; 145():192-199. PubMed ID: 30509708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database.
    Price DB; Gefen E; Gopalan G; Miglio C; McDonald R; Thomas V; Wan Yau Ming S
    Pragmat Obs Res; 2017; 8():69-83. PubMed ID: 28572742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
    Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of severe exacerbations, poor asthma control, and β-agonist overuse for patients with asthma.
    Patel M; Pilcher J; Reddel HK; Qi V; Mackey B; Tranquilino T; Shaw D; Black P; Weatherall M; Beasley R;
    J Allergy Clin Immunol Pract; 2014; 2(6):751-8. PubMed ID: 25439367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA; Buhl R; Lawrence D; Young D
    Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
    N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.
    Bollu V; Ernst FR; Karafilidis J; Rajagopalan K; Robinson SB; Braman SS
    Int J Chron Obstruct Pulmon Dis; 2013; 8():631-9. PubMed ID: 24353413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes.
    Bosnic-Anticevich S; Chrystyn H; Costello RW; Dolovich MB; Fletcher MJ; Lavorini F; Rodríguez-Roisin R; Ryan D; Wan Yau Ming S; Price DB
    Int J Chron Obstruct Pulmon Dis; 2017; 12():59-71. PubMed ID: 28053517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation.
    Sharafkhaneh A; Altan AE; Colice GL; Hanania NA; Donohue JF; Kurlander JL; Rodriguez-Roisin R; Altman PR
    Respir Med; 2014 Sep; 108(9):1310-20. PubMed ID: 25130680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
    Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
    Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.